Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2022 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
February 15, 2022 07:30 ET | Source: Zai Lab Limited

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
February 07, 2022 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentation at February Investor Conference

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
January 12, 2022 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical...
January 06, 2022 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
December 29, 2021 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentations at January Investor Conferences

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical...
December 22, 2021 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
December 17, 2021 18:09 ET | Source: Zai Lab Limited

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

VYVGART is the first and only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the...
December 16, 2021 04:43 ET | Source: Zai Lab Limited

China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline NUZYRA is Zai Lab’s...
December 03, 2021 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right